Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension.
暂无分享,去创建一个
Shujing Jane Lim | A. Chan | A. Shaaban | M. Robinson | T. Kendall | D. Harrison | D. O’Connor | D. Brierley | Ian Lewis
[1] Shujing Jane Lim,et al. Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta‐aggregation , 2021, The journal of pathology. Clinical research.
[2] H. Gevensleben,et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial , 2020, The Lancet. Oncology.
[3] Xiaoxuan Liu,et al. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension , 2020, Nature medicine.
[4] C. Swanton,et al. The National Lung Matrix Trial of personalized therapy in lung cancer , 2020, Nature.
[5] E. Provenzano,et al. The important role of the histopathologist in clinical trials: challenges and approaches to tackle them , 2020, Histopathology.
[6] R. Kravitz,et al. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist , 2020, BMJ.
[7] C. Moskaluk,et al. Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. , 2019, American journal of clinical pathology.
[8] Jens Rittscher,et al. The use of digital pathology and image analysis in clinical trials , 2019, The journal of pathology. Clinical research.
[9] Karin Oien,et al. Training and accreditation standards for pathologists undertaking clinical trial work , 2019, The journal of pathology. Clinical research.
[10] Karin Oien,et al. Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work , 2018, The journal of pathology. Clinical research.
[11] Joanna Coast,et al. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension , 2018, JAMA.
[12] K. O’Brien,et al. Development of a core outcome set for orthodontic trials using a mixed-methods approach: protocol for a multicentre study , 2017, Trials.
[13] Timothy J. Wood,et al. Using consensus group methods such as Delphi and Nominal Group in medical education research* , 2017, Medical teacher.
[14] Emilio Bria,et al. Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. , 2016, Breast.
[15] L. Esserman,et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group , 2015, Modern Pathology.
[16] C. Röcken. Quality assurance in clinical trials—the role of pathology , 2015, Virchows Archiv.
[17] Harlan M Krumholz,et al. Increasing value and reducing waste: addressing inaccessible research , 2014, The Lancet.
[18] R. Tibshirani,et al. Increasing value and reducing waste in research design, conduct, and analysis , 2014, The Lancet.
[19] I. Nagtegaal,et al. Pathology is a necessary and informative tool in oncology clinical trials , 2014, The Journal of pathology.
[20] Anil V Parwani,et al. Central pathology review for phase III clinical trials: the enabling effect of virtual microscopy. , 2013, Archives of pathology & laboratory medicine.
[21] D. Rennie,et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. , 2013, Annals of internal medicine.
[22] David Moher,et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials , 2013, BMJ.
[23] Joshua LaBaer,et al. Improving international research with clinical specimens: 5 achievable objectives. , 2012, Journal of proteome research.
[24] N. Chalasani,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.
[25] Jacqueline A. Hall,et al. Integrating collection of biospecimens in clinical trials: the approach of the European organization for research and treatment of cancer. , 2011, Biopreservation and biobanking.
[26] R. Schilsky,et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Lawrence D. True,et al. Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents , 2010, Clinical Cancer Research.
[28] Anna Kelsey,et al. Central pathology review in multicenter trials and studies , 2009, Cancer.
[29] Marcella Sarzotti-Kelsoe,et al. Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials , 2009, PLoS medicine.
[30] D. Altman,et al. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation , 2007, Trials.
[31] D. Ruiter,et al. The role of the EORTC pathologist in clinical trials: achievements and perspectives. European Organisation for Research and Treatment of Cancer. , 2002, European journal of cancer.
[32] I. Olkin,et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.